BioCentury | Feb 14, 2020
Targets & Mechanisms

Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors

...new class of therapeutic oligonucleotides -- stem loop RNAs (SLR) -- that can activate the RIG-I...
...and poorly immunogenic tumors, including melanoma and colon cancer tumor and metastasis models. Activation of RIG-I...
...efficacy. Targets IFNγ - Interferon gamma PD-1 (PDCD1; CD279) - Programmed cell death 1 RIG-1 (DDX58...
BioCentury | Dec 27, 2019
Clinical News

Spring Bank’s HBV therapy on hold after signs of liver damage

...and enrollment of all clinical studies of the small molecule-nucleic acid hybrid that agonizes RIG-I. RIG-I...
...the RIG-I agonist was well tolerated with no systemic interferon-life effects. The immunostimulatory functions of RIG-I...
...RIG-I (DDX58) - DEAD box polypeptide 58 Sandi Wong, Staff Writer Inarigivir soproxil (sb 9200) Spring Bank Pharmaceuticals Inc. DEAD box polypeptide 58 (RIG-I) (DDX58)...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...targets, two immune proteins better know for their therapeutic potential now show promise as biomarkers. RIG-I...
...combinations of RIG-I activators with CTLA-4 inhibitors, according to ClinicalTrials.gov. The most advanced program targeting RIG-I...
...PDCD1; CD279) - Programmed cell death 1 RFC5 - Replication factor C subunit 5 RIG-I (DDX58...
BioCentury | Jul 31, 2019
Finance

How Wellington closed its largest fund yet at €210M

Takeouts of portfolio companies Rigontec and Symetis, coupled with a focus on biotechs in Germany, Austria and Switzerland, helped Wellington Partners raise its largest fund to date. Wellington announced Wednesday the close of Wellington Partners...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...its Phase II ACHIEVE trial of Inarigivir soproxil, a small molecule nucleic acid hybrid targeting RIG-I...
...domain family member 15 PDGFRA (PDGFR2; CD140A) - Platelet derived growth factor receptor A RIG-I (DDX58...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...Bank’s Inarigivir soproxil, a small molecule nucleic acid hybrid targeting DEAD box polypeptide 58 (RIG-I; DDX58...
BioCentury | Aug 10, 2018
Clinical News

Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

...2019. Inarigivir is a small molecule nucleic acid hybrid targeting DEAD box polypeptide 58 (RIG-I; DDX58...
...NASDAQ:SBPH), Hopkinton, Mass. Product: Inarigivir soproxil Business: Infectious Molecular target: DEAD box polypeptide 58 (RIG-I; DDX58...
...caspase recruitment domain family member 15 (NOD2; CARD15) Description: Small molecule nucleic acid hybrid targeting RIG-I...
BioCentury | Aug 7, 2018
Company News

Icahn urges Cigna shareholders to oppose Express Scripts deal

Activist investor Carl Icahn sent a letter Tuesday urging shareholders of Cigna Corp. (NYSE:CI) to vote down its proposed acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). Affiliates of Icahn own about 0.56% of Cigna's outstanding...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

...recently by Lewis Cantley’s group. BC: You’ve also discovered the protein MAVS, an adaptor for RIG-I...
...that front, and recently there was a company that targeted the RIG-I pathway, that developed RIG-I...
...cGAMP - cyclic GMP-AMP cGAS - cGAMP synthase MAVS - Mitochondrial antiviral signaling protein RIG-I (DDX58...
BioCentury | Mar 7, 2018
Politics & Policy

Gottlieb slams ‘Kabuki’ biosimilar pricing schemes

FDA Commissioner Scott Gottlieb Wednesday criticized PBMs and payers for creating “Kabuki” drug pricing schemes “that obscure profit taking across the supply chain that drives up costs; that expose consumers to high out-of-pocket spending; and...
Items per page:
1 - 10 of 99